Minimal Important Difference (MID) of Response to the Hepatitis-C Virus Patient Reported Outcomes (HCV-PRO) Instrument in a Trial of Pegylated Interferon/Ribavirin (pegIFN/RBV) and Direct-Acting-Antivirals (DAA)
Nov 1, 2013, 00:00
10.1016/j.jval.2013.08.233
https://www.valueinhealthjournal.com/article/S1098-3015(13)02138-4/fulltext
Title :
Minimal Important Difference (MID) of Response to the Hepatitis-C Virus Patient Reported Outcomes (HCV-PRO) Instrument in a Trial of Pegylated Interferon/Ribavirin (pegIFN/RBV) and Direct-Acting-Antivirals (DAA)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)02138-4&doi=10.1016/j.jval.2013.08.233
First page :
A362
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
220